BIOA (BioAge Labs, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BIOA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Shane Barton | Principal Accounting Officer | MIXED | — | — |
| 2026-06-12 | Rekha Hemrajani | Director | A | — | — |
| 2026-06-12 | Michael H. Davidson | Director | A | — | — |
| 2026-06-12 | JAMES HEALY | Director | A | — | — |
| 2026-06-12 | Vijay Satyanand Pande | Director | A | — | — |
| 2026-06-12 | JEAN PIERRE GARNIER | Director | A | — | — |
| 2026-06-12 | PATRICK G ENRIGHT | Director | A | — | — |
| 2026-04-24 | DOV A MD GOLDSTEIN | Chief Financial Officer | M | — | — |
| 2026-04-03 | PAUL D RUBIN | Chief Medical Officer | MIXED | — | — |
| 2026-03-03 | PAUL D RUBIN | Chief Medical Officer | MIXED | — | — |
| 2026-03-03 | DOV A MD GOLDSTEIN | Chief Financial Officer | M | — | — |
| 2026-02-19 | PAUL D RUBIN | Chief Medical Officer | A | — | — |
| 2026-02-19 | Eric Morgen | Chief Operating Officer | A | — | — |
| 2026-02-19 | DOV A MD GOLDSTEIN | Chief Financial Officer | A | — | — |
| 2026-02-19 | Shane Barton | Principal Accounting Officer | A | — | — |
| 2026-02-19 | Kristen Fortney | Chief Executive Officer | A | — | — |
| 2026-02-03 | DOV A MD GOLDSTEIN | Chief Financial Officer | M | — | — |
| 2026-02-03 | PAUL D RUBIN | Chief Medical Officer | MIXED | — | — |
| 2026-01-21 | DOV A MD GOLDSTEIN | Chief Financial Officer | M | — | — |
| 2026-01-15 | Kristen Fortney | Chief Executive Officer | Sell | — | — |
| 2026-01-15 | DOV A MD GOLDSTEIN | Chief Financial Officer | MIXED | — | — |
| 2026-01-06 | PAUL D RUBIN | Chief Medical Officer | MIXED | — | — |
| 2025-12-11 | PAUL D RUBIN | Chief Medical Officer | MIXED | — | — |
| 2025-12-05 | PAUL D RUBIN | Chief Medical Officer | MIXED | — | — |
| 2025-08-11 | Vijay Satyanand Pande | Director | A | — | — |
| 2025-06-09 | Michael H. Davidson | Director | A | — | — |
| 2025-06-09 | PATRICK G ENRIGHT | Director | A | — | — |
| 2025-06-09 | JAMES HEALY | Director | A | — | — |
| 2025-06-09 | JEAN PIERRE GARNIER | Director | A | — | — |
| 2025-06-09 | Rekha Hemrajani | Director | A | — | — |
| 2025-03-10 | Shane Barton | Principal Accounting Officer | Buy | — | — |
| 2025-03-10 | Rekha Hemrajani | Director | Buy | — | — |
| 2025-02-25 | Eric Morgen | Chief Operating Officer | A | — | — |
| 2025-02-20 | Eric Morgen | Chief Operating Officer | A | — | — |
| 2025-02-20 | Kristen Fortney | Chief Executive Officer | A | — | — |
| 2025-02-20 | Shane Barton | Principal Accounting Officer | A | — | — |
| 2025-02-20 | DOV A MD GOLDSTEIN | Chief Financial Officer | A | — | — |
| 2025-02-20 | PAUL D RUBIN | Chief Medical Officer | A | — | — |
| 2024-12-20 | Shane Barton | Principal Accounting Officer | A | — | — |
| 2024-10-03 | Vijay Satyanand Pande | Director | Buy | — | — |
| 2024-10-01 | Cormorant Private Healthcare Fund IV LP | — | MIXED | — | — |
| 2024-09-27 | Kristen Fortney | Chief Executive Officer | A | — | — |
| 2024-09-27 | PATRICK G ENRIGHT | Director | MIXED | — | — |
| 2024-09-27 | Michael H. Davidson | Director | A | — | — |
| 2024-09-27 | Eric Morgen | Chief Operating Officer | A | — | — |
| 2024-09-27 | JEAN PIERRE GARNIER | Director | A | — | — |
| 2024-09-27 | Rekha Hemrajani | Director | A | — | — |
| 2024-09-27 | Vijay Satyanand Pande | Director | MIXED | — | — |
| 2024-09-27 | JAMES HEALY | Director | MIXED | — | — |
| 2017-12-04 | Kenneth W. Wall | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,227,124 | — |
| — | Director | 1,310,589 | — |
| — | — | 1,179,529 | — |
| — | Director | 1,093,889 | — |
| — | Chief Executive Officer | 976,949 | — |
| — | Chief Financial Officer | 36,575 | — |
| — | Principal Accounting Officer | 11,933 | — |
| — | Chief Medical Officer | 5,437 | — |
| — | Director | 3,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIOA quote page; the site-wide leaderboard is on the insider transactions hub.